Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).
Ovarian Cancer
DRUG: Apatinib and Etoposide capsule|DRUG: Apatinib
Objective response rate (ORR) by investigator, ORR was defined as the proportion of subjects who have a complete or partial response relative to baseline ., up to 2 years
AEs+SAEs, Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0, 30 days after the last dose|PFS by investigator, PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria., up to 2 years|Overall Survival (OS), OS is the time interval from the date of randomization to death from any cause., up to 3 years|Pharmacokinetic characteristic, Evaluation of PK parameters Tmax of apatinib or etoposide in plasma, up to 2 years|Pharmacokinetic characteristic, Evaluation of PK parameters Cmax of apatinib or etoposide in plasma, up to 2 years|Pharmacokinetic characteristic, Evaluation of PK parameters t1/2 of apatinib or etoposide in plasma, up to 2 years|Pharmacokinetic characteristic, Evaluation of PK parameters AUC0-t of apatinib or etoposide in plasma, up to 2 years
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).